Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Metformin as add-on Therapy in Non-Diabetic Heart Failure Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic heart failure (\>6 months duration)~* Stabilized on recommended or maximally tolerated dose of ACE-I/ARB or ARNI (unless contraindicated) and beta-blocker (unless contraindicated). If indicated, an aldosterone receptor antagonist should be given (unless contraindicated).~* Reduced ejection fraction defined as LVEF \< 45%~* NYHA-class II or III or IV with stable symptoms for at least the past 3 months~* Creatinine clearance \> 45 ml/min~Exclusion Criteria:~* Diabetes mellitus: Diabetes will be diagnosed using the 2018 The American Diabetes Association (ADA) Standards of Medical Care in Diabetes 15~  * FPG ≥126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for at least 8 h.\*~ * 2-h PG ≥200 mg/dL (11.1 mmol/L) during OGTT. The test should be performed as described by the WHO, using a glucose load containing the equivalent of 75-g anhydrous glucose dissolved in water.~ * A1C ≥6.5% (48 mmol/mol). The test should be performed in a laboratory using a method that is NGSP certified and standardized to the DCCT assay.\*~ * In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥200 mg/dL (11.1 mmol/L).~* Any oral or injectable hypoglycemic therapy (e.g. insulin, sulfonylureas)~* Recent Hospitalizations in the past 3 months~* Metformin treatment within the last 3 months~* Creatinine clearance below 45 in the prior 6 months as assessed by Cockcroft and Gault equation~* Known allergy to metformin or major side effects to metformin treatment~* Atrial fibrillation with poorly controlled ventricular rate at rest (\> 100 beats/min)~* Hypertrophic cardiomyopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: EXPERIMENTAL): Patients in the metformin group will receive a starting dose of 1000 mg/day. The dose will be titrated as tolerated to a maximum of 2000 mg/. Patients will receive the medications for six year and will be followed up for the duration of the study. Patients will be assessed at baseline, 3 months, and 6 months.
- Standard of Care (Type: NO_INTERVENTION): Patients in the control arm will continue the SOC medications

Based on this trial design, predict the completion outcome and termination type (if applicable).